Powered by Google Google ÜbersetzerGoogle Übersetzer
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Latest Press Releases
View all
TimeHeadline
10h agoDelivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
11h agoRefers to Item 7 on the agenda: Report on the audit of the consolidated financial statements of Grupa Kęty SA
13h agoThe 4th BOCHK Science and Technology Innovation Prize Award Ceremony Concludes with Great Success
20h agoBuffalo Potash Files Annual Information Form and New Technical Report
21h agoIonik Announces 30-Day Extension of Senior Debt Facility
Roivant Sciences Ltd. logo

Roivant Sciences Ltd.

About

29.96USD-0.92 -2.98%
Closed • Updated at 00:25 GMT+00:00
Market Cap$21.55B
Volume5.87M
Beta0.61
RSI54.60
Gross Margin43.91%
Health TechnologyPharmaceuticals: Major

Roivant Sciences Ltd. — investor relations, events, news, and company updates on 6ix.

Latest News

May 20 2026
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
May 20 2026
Roivant Sciences : Annual Report for Fiscal Year Ending March 31, 2025 (Form 10-K)
May 11 2026
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026
Apr 2 2026
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
Apr 2 2026
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Community Chat

Ask AI

Try asking
6ix6ixAIEvents